Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aee-788. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aee-788 SCHEMBL29973591 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29478848 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL1738023 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29389001 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613756 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL10259799 | 0.99 | EGFR (0.98) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93737 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93738 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4767093 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27585261 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| US-20100278824-A1 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | FIDLER ISAIAH JOSH | 2010-11-04 | — | — | US | claimed |
| EP-1819331-B1 | COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | claimed |
| US-20080219977-A1 | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2008-09-11 | — | — | US | claimed |
| WO-2007014335-A2 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-01 | — | — | WO | claimed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-24 | — | — | US | disclosed |
| US-12152027-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-26 | — | — | US | disclosed |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2009-05-07 | — | — | US | disclosed |
| CN-101370814-A | Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents | NOVARTIS AG (CH) | 2009-02-18 | — | — | CN | disclosed |
| CN-101370814-A | Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents | NOVARTIS AG (CH) | 2009-02-18 | — | — | CN | disclosed |
| EP-1979357-A1 | SOLID FORMS OF A PYRROLOPYRIMIDINE DERIVATIVE AND THEIR USE AS ANTI-TUMOR AGENTS | Novartis AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008115890-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007082946-A1 | SOLID FORMS OF A PYRROLOPYRIMIDINE DERIVATIVE AND THEIR USE AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171777-B2 | Methods of making a cyclic dinucleotide | STING1, CGAS, MAVS | EGFR 4313/4885KDR 4069/4885ERBB2 3441/4885 |
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | EGFR 4421/4885KDR 4667/4885ERBB2 4212/4885 |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | EGFR 2469/4885KDR 3722/4885ERBB2 2275/4885 |
| US-20090137595-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | KDR, FLT1, FLT4 | EGFR 108/4885KDR 1/4885ERBB2 31/4885 |
| US-20090118324-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | EGFR 311/4885KDR 642/4885ERBB2 145/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | EGFR 918/4885KDR 1760/4885ERBB2 717/4885 |
| US-20100278824-A1 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | PDGFRA, PDGFRB, TEK | EGFR 6/4885KDR 4/4885ERBB2 8/4885 |
| US-12152027-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | EGFR 4421/4885KDR 4667/4885ERBB2 4212/4885 |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | CDK1, CDK12, CDK15 | EGFR 1992/4885KDR 1955/4885ERBB2 808/4885 |
| US-20080219977-A1 | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer | PDGFRA, PDGFRB, TEK | EGFR 6/4885KDR 4/4885ERBB2 8/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | EGFR 20/4885KDR 2/4885ERBB2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.